MX2022015678A - Metodos para tratar o prevenir la enfermedad renal cronica. - Google Patents

Metodos para tratar o prevenir la enfermedad renal cronica.

Info

Publication number
MX2022015678A
MX2022015678A MX2022015678A MX2022015678A MX2022015678A MX 2022015678 A MX2022015678 A MX 2022015678A MX 2022015678 A MX2022015678 A MX 2022015678A MX 2022015678 A MX2022015678 A MX 2022015678A MX 2022015678 A MX2022015678 A MX 2022015678A
Authority
MX
Mexico
Prior art keywords
treating
methods
kidney disease
chronic kidney
preventing chronic
Prior art date
Application number
MX2022015678A
Other languages
English (en)
Spanish (es)
Inventor
Shunqi Yan
Litain Yeh
Rongzi Yan
Zancong Shen
Original Assignee
Arthrosi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics Inc filed Critical Arthrosi Therapeutics Inc
Publication of MX2022015678A publication Critical patent/MX2022015678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
MX2022015678A 2020-06-10 2021-06-09 Metodos para tratar o prevenir la enfermedad renal cronica. MX2022015678A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063037469P 2020-06-10 2020-06-10
US202163195411P 2021-06-01 2021-06-01
PCT/US2021/036620 WO2021252630A1 (en) 2020-06-10 2021-06-09 Methods for treating or preventing chronic kidney disease

Publications (1)

Publication Number Publication Date
MX2022015678A true MX2022015678A (es) 2023-03-14

Family

ID=78846498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015678A MX2022015678A (es) 2020-06-10 2021-06-09 Metodos para tratar o prevenir la enfermedad renal cronica.

Country Status (10)

Country Link
US (1) US20230218563A1 (cg-RX-API-DMAC10.html)
EP (1) EP4164624A4 (cg-RX-API-DMAC10.html)
JP (1) JP7857235B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230024354A (cg-RX-API-DMAC10.html)
AU (1) AU2021288679A1 (cg-RX-API-DMAC10.html)
CA (1) CA3181902A1 (cg-RX-API-DMAC10.html)
IL (1) IL298833A (cg-RX-API-DMAC10.html)
MX (1) MX2022015678A (cg-RX-API-DMAC10.html)
TW (1) TW202214228A (cg-RX-API-DMAC10.html)
WO (1) WO2021252630A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2291189B1 (en) 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2014149789A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treament of hyperuricemia
AU2017298142B2 (en) * 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
WO2019195118A1 (en) * 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2020070539A1 (en) * 2018-10-01 2020-04-09 Astrazeneca Ab Compositions for reducing serum uric acid
JP2022511800A (ja) * 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CA3140412A1 (en) * 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia

Also Published As

Publication number Publication date
KR20230024354A (ko) 2023-02-20
US20230218563A1 (en) 2023-07-13
EP4164624A1 (en) 2023-04-19
IL298833A (en) 2023-02-01
EP4164624A4 (en) 2024-10-16
TW202214228A (zh) 2022-04-16
AU2021288679A1 (en) 2023-02-02
JP7857235B2 (ja) 2026-05-12
WO2021252630A1 (en) 2021-12-16
CA3181902A1 (en) 2021-12-16
JP2023529691A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
MX2025002170A (es) Inhibidores de kras g12c
DE60027564D1 (de) Tek-antagonisten
EP4566675A3 (en) Heterocyclic compounds as immunomodulators
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
MX2022000933A (es) Inhibición de ezh2 en tratamientos combinados para el tratamiento del cáncer.
EA200600618A1 (ru) Применение эффекторов глутаминил- и глутаматциклаз
WO2004024134A8 (en) Pharmaceutical formulations of modafinil
MX2010003658A (es) Sistema quirurgico no invasivo basado en fotones que incluye control celular automatico y erradicacacion por control de proalimentacion pre-calculada mas control de retroalimentacion de imagen para suministro enfocado de energia.
EA202191543A1 (ru) Способы лечения или профилактики подагры или гиперурикемии
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
EA202191545A1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
MX2021013980A (es) Compuesto para el tratamiento de gota o hiperuricemia.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
CO2022006367A2 (es) Tratamiento génico para la enfermedad de alzheimer
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
NZ811397A (en) Liquid tasimelteon formulations and methods of use thereof
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2024000634A (es) Compuestos de sulfonimidamida y usos de los mismos.
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
EP1208840A3 (en) Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer